• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 5. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002

Recent Advances in the Application of 3-bromo-4-(1,1-difluoroethyl)pyridine (CAS: 2246373-31-7) in Chemical Biology and Pharmaceutical Research

In recent years, the compound 3-bromo-4-(1,1-difluoroethyl)pyridine (CAS: 2246373-31-7) has emerged as a key intermediate in the synthesis of novel pharmaceuticals and bioactive molecules. This heterocyclic compound, characterized by its unique bromo and difluoroethyl substituents, has attracted significant attention due to its potential applications in drug discovery, particularly in the development of kinase inhibitors and other targeted therapies. The presence of both bromine and fluorine atoms in its structure makes it a versatile building block for further functionalization, enabling the creation of diverse molecular architectures with tailored biological activities.

A recent study published in the Journal of Medicinal Chemistry (2023) demonstrated the utility of 3-bromo-4-(1,1-difluoroethyl)pyridine in the synthesis of potent and selective JAK3 inhibitors. The researchers utilized this compound as a key intermediate to introduce the difluoroethyl group, which was found to significantly enhance the metabolic stability and target binding affinity of the resulting inhibitors. The study reported IC50 values in the low nanomolar range for several synthesized compounds, highlighting the importance of this building block in optimizing drug-like properties.

Another significant application of 3-bromo-4-(1,1-difluoroethyl)pyridine was reported in the field of PET (Positron Emission Tomography) tracer development. Researchers at a leading pharmaceutical company incorporated this compound into a novel tracer for imaging neuroinflammation. The difluoroethyl group proved crucial for achieving optimal blood-brain barrier penetration and target specificity, as demonstrated in preclinical studies using rodent models of neurodegenerative diseases. This work, published in ACS Chemical Neuroscience (2023), opens new possibilities for non-invasive monitoring of neuroinflammatory processes in vivo.

From a synthetic chemistry perspective, several innovative methodologies have been developed to access 3-bromo-4-(1,1-difluoroethyl)pyridine and its derivatives. A 2023 publication in Organic Letters described a novel palladium-catalyzed cross-coupling approach that allows for efficient functionalization of the bromo position while preserving the sensitive difluoroethyl moiety. This methodological advance has significantly expanded the structural diversity of compounds that can be derived from this key intermediate, facilitating more efficient structure-activity relationship studies in drug discovery programs.

The pharmacological profile of compounds containing the 3-bromo-4-(1,1-difluoroethyl)pyridine scaffold continues to be explored in various therapeutic areas. Recent patent applications (2023-2024) reveal its incorporation into candidates for treating autoimmune disorders, oncology indications, and even some viral infections. The unique electronic properties imparted by the difluoroethyl group appear to modulate both the pharmacokinetic and pharmacodynamic properties of these drug candidates, often leading to improved therapeutic indices compared to their non-fluorinated analogs.

Looking forward, the versatility of 3-bromo-4-(1,1-difluoroethyl)pyridine (CAS: 2246373-31-7) suggests it will remain an important tool in medicinal chemistry. Its applications span from serving as a building block in traditional small molecule drug discovery to enabling the development of novel chemical probes for biological target validation. As synthetic methodologies continue to evolve and our understanding of fluorine effects in medicinal chemistry deepens, we anticipate seeing even more innovative uses of this compound in the coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)